Study to Compare the Effects of Repeated Doses of an Investigational New Drug (PF-06946860) and a Placebo on Appetite in Participants With Advanced Cancer and Anorexia
Study to Compare the Effects of Repeated Doses of an Investigational New Drug (PF-06946860) and a Placebo on Appetite in Participants With Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on
 appetite and to find out how participants with advanced cancer and anorexia feel after
 receiving repeated subcutaneous (SC-injected under the skin) doses.
A 6 week double blind study to compare the effects of the investigational new drug
 (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer
 and anorexia feel after receiving repeated doses injected under the skin (subcutaneously).

 During the initial 6-week treatment period (Part A), a total of 2 doses of study drug or
 placebo will be administered 3 weeks apart.. Each dose contains two injections. Part B is an
 optional 18-week open-label treatment period where up to 7 doses of study drug may be
 administered. Part B does not include placebo.

 Assessments include:

 -  Measure the impact of the study drug on appetite, fatigue, and pain questionnaires

 -  Body weight measurements

 -  Blood samples to evaluate safety and additional endpoints including the amount of the
 study drug in the blood and the effects of the study drug on levels of a specific
 cytokine.
Key Inclusion Criteria:

 -  Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast
 or ovarian cancer which, in the treating oncologist's assessment, is considered
 incurable.

 -  Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment
 Appetite 7-day recall scale

 -  Meets any 1 of the following criteria at Randomization:

 -  Not currently receiving antineoplastic therapy

 -  On third line systemic antineoplastic therapy

 -  Receiving chemotherapy or immunotherapy treatment which is considered to be
 without curative intent.

 -  On a stable regimen of systemic antineoplastic therapy.

 -  Signed informed consent.

 Key Exclusion Criteria:

 -  Other forms of cancer not listed in Inclusion Criterion for which treatment has been
 received in the past 6 months

 -  Receiving tube feedings or parenteral nutrition at the time of Screening or
 Randomization.

 -  Current active reversible causes of decreased food intake.

 -  Current, severe gastrointestinal disease

 -  Participants with known symptomatic brain metastases requiring steroids.

 -  Active uncontrolled bacterial, fungal, or viral infection, including HBV, HCV.
 Confirmed positive test for HIV.

 -  Elevated blood pressure uncontrolled by medications.

 -  inadequate renal and liver function.

 -  Women who are pregnant or breast-feeding